Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy-Reference-Cited by-同舟云学术

Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy

Published:2017-10 Issue:10 Volume:101 Page:2612-2620
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Holdaas Hallvard,de Fijter Johan W.,Cruzado Josep M.,Massari Pablo,Nashan Björn,Kanellis John,Witzke Oliver,Gutierrez-Dalmau Alex,Turkmen Aydin,Wang Zailong,Lopez Patricia,Bernhardt Peter,Kochuparampil Jossy,van der Giet Markus,Murbraech Klaus

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference54 articles.

1. OPTN/SRTR 2011 annual data report: kidney;Matas;Am J Transplant,2013

2. Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report;Opelz;Am J Transplant,2012

3. Association between steroid dosage and death with a functioning graft after kidney transplantation;Opelz;Am J Transplant,2013

4. Reduction in cardiovascular death after kidney transplantation;Pilmore;Transplantation,2010

5. Cardiovascular complications after renal transplantation and their prevention;Ojo;Transplantation,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular disease assessment and management in liver transplantation;European Heart Journal;2024-08-17

2. Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation;Transplantation;2023-12-07

3. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study;Transplantation;2023-06-20

4. Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations;American Journal of Transplantation;2022-12

5. Cardiovascular effects of immunosuppression agents;Frontiers in Cardiovascular Medicine;2022-09-21